Published in Adv Cancer Res on January 01, 1975
The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis. Oncogene (2009) 2.14
Identification of a non-H-2 gene (Rfv-3) influencing recovery from viremia and leukemia induced by Friend virus complex. Proc Natl Acad Sci U S A (1979) 1.95
Immune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors: contrasting consequences of host versus tumor evolution. Proc Natl Acad Sci U S A (1977) 1.87
H-2D control of recovery from Friend virus leukemia: H-2D region influences the kinetics of the T lymphocyte response to Friend virus. J Exp Med (1983) 1.28
Signaling defects in anti-tumor T cells. Immunol Rev (2008) 1.28
Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. Proc Natl Acad Sci U S A (1996) 1.27
Chemical carcinogenesis: a biologic perspective. Am J Pathol (1982) 1.26
Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts. Proc Natl Acad Sci U S A (2005) 1.24
Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes. J Virol (2000) 1.22
Depressed immunity and the development of cancer. Clin Exp Immunol (1981) 1.17
Neoplasms arising in CBA mice after transfer of spleen cells from syngeneic old donors. Immunology (1984) 1.07
Immune escape mechanisms of intraocular tumors. Prog Retin Eye Res (2009) 1.07
Immunological ignorance of solid tumors. Springer Semin Immunopathol (2005) 1.05
Do cancers arise from a single transformed cell or is monoclonality of tumours a late event in carcinogenesis? Br J Cancer (1985) 1.04
Radiation-induced augmentation of the response of A/J mice to SaI tumor cells. Am J Pathol (1982) 0.98
Revisiting immunosurveillance and immunostimulation: Implications for cancer immunotherapy. J Transl Med (2005) 0.97
Review: cancer-induced autoimmunity in the rheumatic diseases. Arthritis Rheumatol (2015) 0.94
An immune reaction may be necessary for cancer development. Theor Biol Med Model (2006) 0.94
The initial immune reaction to a new tumor antigen is always stimulatory and probably necessary for the tumor's growth. Clin Dev Immunol (2010) 0.93
H-2D (Rfv-1) gene influence on recovery from Friend virus leukemia is mediated by nonleukemic cells of the spleen and bone marrow. J Exp Med (1980) 0.92
Induction of tolerance to a murine fibrosarcoma in two zones of dosage--the involvement of suppressor cells. Br J Cancer (1986) 0.85
Immunostimulation and immunoinhibition of premalignant lesions. Theor Biol Med Model (2007) 0.85
Tolerance and immune suppression in the tumor microenvironment. Cell Immunol (2015) 0.84
Factors affecting stimulation of natural cytotoxicity to a rat lymphoma by Corynebacterium parvum. Br J Cancer (1980) 0.83
Immunotherapy for solid tumors--a review for surgeons. J Surg Res (2013) 0.83
Microcirculation of the lymph node with metastases. Am J Pathol (1976) 0.82
Cancer immunotherapy by immunosuppression. Theor Biol Med Model (2010) 0.82
Natural killer cells. In vitro and in vivo. Am J Pathol (1978) 0.82
Viral infection-homograft interactions in a murine model. J Clin Invest (1978) 0.81
The concept of immune surveillance against tumors. The first theories. Oncotarget (2016) 0.80
Revisiting cancer immunoediting by understanding cancer immune complexity. J Pathol (2011) 0.80
Dynamics of the cell-mediated immune response to tumour growth. Philos Trans A Math Phys Eng Sci (2017) 0.79
Tumor immunogenicity: how far can it be pushed? Proc Natl Acad Sci U S A (1993) 0.78
Tumor-induced immunosuppression. Am J Pathol (1978) 0.78
On the nature of cancer and why anticancer vaccines don't work. Cancer Cell Int (2005) 0.78
In vitro cytotoxicity and transplantation protection by autologous natural and activated killer cells against an in vitro transformed tumorigenic fibroblast line. A case study. J Clin Invest (1985) 0.78
Switching on the macrophage-mediated suppressor mechanism by tumor cells to evade host immune surveillance. Proc Natl Acad Sci U S A (1980) 0.76
Organ and tumour antigens in malignant disease: a review. J R Soc Med (1978) 0.76
Intraperitoneal immunotherapy: historical perspectives and modern therapy. Cancer Gene Ther (2016) 0.75
B16 melanoma development, NK activity cytostasis and natural antibodies in 3 and 12 month old mice. Br J Cancer (1984) 0.75
Incidence of spontaneous tumours in neonatally thymectomized rats. Br J Cancer (1978) 0.75
Release of lymphotoxin by control and chemical carcinogen-treated lymphocyte cultures derived from black healthy subjects and cancer patients. J Natl Med Assoc (1982) 0.75
Intrathymic and extrathymic T cell maturation. Immunol Rev (1978) 2.47
Deficient immunologic functions of NZB mice. Proc Soc Exp Biol Med (1968) 2.41
Natural cytotoxic cells against solid tumors in mice. I. Strain and age distribution and target cell susceptibility. J Immunol (1978) 2.06
Autoimmune phenomena and renal disease in mice. Role of thymectomy, aging, and involution of immunologic capacity. Lab Invest (1970) 1.69
Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science (1974) 1.68
Ly phenotype of T cells cytotoxic for syngeneic mouse mammary tumors: evidence for T cell interactions. Proc Natl Acad Sci U S A (1977) 1.65
Immunocompetence of embryonic hemopoietic cells after traffic to thymus. Transplant Proc (1971) 1.49
Natural cytotoxic cells against solid tumors in mice. II. Some characteristics of the effector cells. J Immunol (1978) 1.41
Chromatographic Separation and Antigenic Analysis of Proteins of the Oncornaviruses IV. Biochemical Typing of Murine Viral Proteins. J Virol (1975) 1.41
Studies on thymus function. I. Cooperative effect of thymic function and lymphohemopoietic cells in restoration of neonatally thymectomized mice. J Exp Med (1970) 1.38
Thymus: an essential factor in lymphoid repopulation. Transplant Proc (1969) 1.36
Lymphocyte subpopulations in NZB mice: deficit of thymus-dependent lymphocytes. J Immunol (1972) 1.34
Studies on thymus function. II. Cooperative effect of newborn and embryonic hemopoietic liver cells with thymus function. J Exp Med (1970) 1.27
Studies on thymus products. 3. Epithelial origin of the serum thymic factor. Immunology (1974) 1.27
Functions of the lymphocytes. Semin Hematol (1969) 1.25
Carcinogen-induced tumors of the thymus. IV. Humoral influences of normal thymus and functional thymomas and influence of posthymectomy period on restoration. J Exp Med (1969) 1.24
Changes in suppressor mechanisms during postnatal development in mice. J Exp Med (1978) 1.22
Carcinogen-induced tumors of the thymus. I. Restoration of neonatally thymectomized mice with a functional thymoma. J Natl Cancer Inst (1968) 1.17
L3T4+ cytotoxic T lymphocytes specific for class I H-2 antigens are activated in primary mixed lymphocyte reactions. J Immunol (1987) 1.16
Natural cytotoxic cells against solid tumors in mice: blocking of cytotoxicity by D-mannose. Proc Natl Acad Sci U S A (1980) 1.16
Postthymic T-cell development. Immunol Rev (1986) 1.15
Carcinogen-induced tumors of the thymus. 3. Restoration of neonatally thymectomized mice with thymomas in cell-impermeable chambers. J Natl Cancer Inst (1969) 1.14
Ia-dependent interleukin 2 production in syngeneic cellular interactions. J Immunol (1982) 1.13
Normal levels of natural cytotoxic cells against solid tumours in NK-deficient beige mice. Nature (1981) 1.12
Enumeration of IL 2-secreting helper T cells by limiting dilution analysis, and demonstration of unexpectedly high levels of IL 2 production per responding cell. J Immunol (1982) 1.12
T cell repopulation from functionally restricted splenic progenitors: 10,000-fold expansion documented by using limiting dilution analyses. J Immunol (1984) 1.12
Long term effects on immune function of early nutritional deprivation. Nature (1973) 1.12
Chemical carcinogenesis in nude mice: comparison between nude mice from homozygous matings and heterozygous matings and effect of age and carcinogen dose. J Natl Cancer Inst (1979) 1.07
Two main features of T-cell development: thymus traffic and postthymic maturation. Contemp Top Immunobiol (1977) 1.05
Natural cytotoxic cells against solid tumors in mice. III. A comparison of effector cell antigenic phenotype and target cell recognition structures with those of NK cells. J Immunol (1981) 1.05
Interleukin 2, production in the syngeneic mixed lymphocyte reaction. Eur J Immunol (1981) 1.04
Suppressor T cells activated in a primary in vitro response to non-major histocompatibility alloantigens. J Exp Med (1982) 1.04
Decline, in aging mice, of the anti-2,4,6-trinitrophenyl (TNP) cytotoxic T cell response attributable to loss of Lyt-2-, interleukin 2-producing helper cell function. Eur J Immunol (1981) 1.03
The Qa-1 antigenic system. Relation of Qa-1 phenotypes to lymphocyte sets, mitogen responses, and immune functions. J Exp Med (1978) 1.03
The activity of natural cytotoxic cells is augmented by interleukin 2 and interleukin 3. J Exp Med (1983) 1.02
Studies of delayed hypersensitivity to L. Monocytogenes in mice: nature of cells involved in passive transfers. Cell Immunol (1973) 1.01
Nonspecific suppression of tumor growth by an immune reaction to Listeria monocytogenes. J Natl Cancer Inst (1974) 1.01
Leukemogenic activity of murine type C viruses after long-term passage in vitro. Int J Cancer (1976) 1.01
Graft-versus-host reactions induced by transplantation of parental strain thymus in neonatally thymectomized F1 hybrid mice. Transplantation (1968) 1.01
Humoral thymic factors influencing postthymic cells. Ann N Y Acad Sci (1975) 1.00
Specific neonatally induced tolerance to Mls locus determinants. J Immunol (1985) 1.00
Correlation of in vitro and in vivo studies of antigens relevant to the control of murine breast cancer. Cancer Res (1976) 1.00
Lyt 1 cells respond to Ia-bearing macrophages in the murine syngeneic mixed lymphocyte reaction. Eur J Immunol (1980) 0.99
Tolerance induction with thymus grafts in neonatally thymectomized mice. J Immunol (1969) 0.99
Spontaneous mammary adenocarcinoma in mice: influence of thymectomy and reconstitution with thymus grafts or spleen cells. Cancer Res (1969) 0.98
TNF regulates thymocyte production by apoptosis and proliferation of the triple negative (CD3-CD4-CD8-) subset. J Immunol (2000) 0.97
Ontogeny of culture-generated suppressor cells. J Exp Med (1979) 0.95
Primary in vitro cytotoxic T cell response to non-major histocompatibility complex alloantigens in normal mice. J Exp Med (1982) 0.94
Reversal of post-thymectomy wasting disease in mice by multiple thymus grafts. J Immunol (1967) 0.94
Morphological and functional studies of fetal thymus transplants in mice. J Exp Med (1972) 0.92
Acceptance of phenotypically differing cultured skin in man and mice. Transplant Proc (1973) 0.91
Protection of lethally irradiated mice by spleen cells from neonatally thymectomized mice. Proc Natl Acad Sci U S A (1974) 0.90
Independent inhibition of IL 2 synthesis and cell proliferation by anti-Ia antibodies in mixed lymphocyte responses to Mls. Eur J Immunol (1984) 0.90
Cell interactions in the suppression of in vitro antibody responses. J Exp Med (1976) 0.89
Resistance to Friend leukemia virus in mice: effect of immunosuppression. J Natl Cancer Inst (1972) 0.89
Limiting dilution analysis of T helper cell heterogeneity: a single class of T cell makes both IL 2 and IL 3. J Immunol (1983) 0.89
Use of positively selected Lyt-2+ mouse splenocytes to examine interleukin-2 secretion in responses to alloantigens and to TNP-modified syngeneic cells. Cell Immunol (1982) 0.89
Murine non-lymphoid tumors are lysed by a combination of NK and NC cells. Int J Cancer (1983) 0.89
Carcinogen-induced immune depression: absence in mice resistant to chemical oncogenesis. Science (1969) 0.88
Analysis by limiting dilution of interleukin 2-producing T cells in murine ontogeny. Eur J Immunol (1983) 0.88
Post-thymectomy autoimmune phenomena in mice. II. Morphologic observations. Lab Invest (1969) 0.87
Multiple lymphokine production by a phorbol ester-stimulated mouse thymoma: relationship to cell cycle events. J Natl Cancer Inst (1983) 0.86
Fine structure of a transplanted chemically induced nonlymphoid thymoma. Cancer Res (1969) 0.86
Delayed tumour appearance and absence of regression in nude mice infected with murine sarcoma virus. Nature (1975) 0.86
Studies on thymus function. 3. Duration of thymic function. J Exp Med (1972) 0.86
Specific neonatal induction of functional tolerance to allogeneic Mls determinants occurs intrathymically and the tolerant state is Mls haplotype-specific. J Immunol (1989) 0.86
Cell-mediated immunity and aging. Fed Proc (1974) 0.86
Reversal of post-thymectomy wasting in mice with immunocompetent cells: influence of histocompatibility differences. J Immunol (1969) 0.86
Natural cytotoxic cells against solid tumors in mice. IV. Natural cytotoxic (NC) cells are not activated natural killer (NK) cells. Int J Cancer (1982) 0.86
Culture-generated suppressor cells: evidence for an adherent cell component. Cell Immunol (1981) 0.85
Thymic lymphomas mediate non-MHC-restricted, TNF-dependent lysis of the murine sarcoma WEHI-164. Cell Immunol (1991) 0.85
Cellular immunity during pregnancy. I. Proliferative and cytotoxic reactivity of paraaortic lymph nodes. Am J Reprod Immunol (1980) 0.85
Spontaneous tumors in nude mice: effect of the viable yellow gene. Exp Cell Biol (1979) 0.85
Growth abnormalities of cultured human skin fibroblasts derived from individuals with hereditary adenomatosis of the colon and rectum. J Cell Physiol (1976) 0.83
Early loss of precursors of CTL and IL 2-producing cells in the development of neonatal tolerance to alloantigens. J Immunol (1984) 0.83
Tumor bearer T cells suppress BCG-potentiated antitumor responses II. Characteristics of the efferent phase suppressor. Cell Immunol (1982) 0.82
Antitumor immune surveillance by tumor necrosis factor producing cells. Immunol Res (1991) 0.81
The lymphoid system. Annu Rev Physiol (1970) 0.81
The cells responsible for murine natural cytotoxic (NC) activity: a multi-lineage system. J Immunol (1986) 0.81
Cell cycle-dependent tumor necrosis factor apoptosis. Cancer Res (1996) 0.81
Inhibition of graft-versus-host reactions in mice by host-directed antibody. Effect of serum dose and immunoglobulin subclass. Transplantation (1974) 0.81
L3T4+, B2A2+ thymocytes from infant mice produce IL 2 after interaction with accessory cells expressing self class II antigens. J Immunol (1986) 0.81
Monoclonal antibody to Lyt 2 antigen blocks H-2I- and H-2K- specific mouse cytotoxic T cells. Nature (1982) 0.80
Functional activity of a chemically induced thymic sarcoma. Lancet (1967) 0.80
Thymus, immunity and autoimmunity. Ann N Y Acad Sci (1971) 0.80
Heterogeneity of lymphocyte populations. Rev Eur Etud Clin Biol (1972) 0.80
Allogeneic radiation chimeras respond to TNP-modified donor and host targets. J Immunol (1980) 0.80
Natural cytotoxic (NC) activity: a multi-lineage system regulated by IL-2. Immunol Res (1986) 0.79
Differential susceptibility of cytotoxic and helper T cell precursors to neonatal tolerization to histocompatibility antigens. J Immunol (1986) 0.79
Phenotypic heterogeneity of antisyngeneic tumor killer cells (ASTK) generated in allogeneic mixed lymphocyte reactions. J Immunol (1984) 0.79
Characterization of T lymphocyte subsets with monoclonal antibodies: discovery of a distinct marker, Ly-m22, of T suppressor cells. J Immunol (1983) 0.79
Blood-group isoantigens in leukemic cells: reversibility of isoantigenic changes by neuraminidase. J Natl Cancer Inst (1971) 0.79
Anti-L3T4 antibody inhibits the lysis of H-2 class II antigen-negative target cells by L3T4+ cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1988) 0.79
Natural cytotoxic cells against solid tumors in mice: a comparison with natural killer cells. Fed Proc (1981) 0.78
Duration of thymic function. Ser Haematol (1974) 0.78
Fetal thymus transplantation: experimental and clinical observations. Birth Defects Orig Artic Ser (1975) 0.78
Comparison of cellular immune changes in the draining paraaortic lymph nodes in syngeneic and allogeneic pregnancies. Prog Clin Biol Res (1981) 0.78
Tumor growth in vivo selects for resistance to tumor necrosis factor. J Immunol (1989) 0.78
Ontogeny of regulatory cells. Fed Proc (1979) 0.78